Translational Behavioral Medicine, published by Oxford University Press, is a premier academic journal dedicated to advancing the field of behavioral medicine through high-quality research and innovative methodologies. With an ISSN of 1869-6716 and an impressive E-ISSN of 1613-9860, the journal serves as a vital platform for disseminating findings that bridge the gap between laboratory research and clinical practice. Ranking in the prestigious Q1 category for both Applied Psychology and Behavioral Neuroscience, it holds a prominent position within the academic community, as reflected by its Scopus rankings—17th out of 88 in Behavioral Neuroscience and 57th out of 249 in Applied Psychology. Although currently non-Open Access, the journal provides a wealth of knowledge for researchers, professionals, and students interested in the interplay of behavioral science and health. With converged years from 2011 to 2024, Translational Behavioral Medicine continues to be an essential resource for those committed to enhancing our understanding of how behavioral factors contribute to health and illness.

American Journal of Hypertension, published by Oxford University Press, is a leading peer-reviewed journal dedicated to the field of hypertension and cardiovascular health. With an ISSN of 0895-7061 and an E-ISSN of 1941-7225, this prestigious journal has been providing researchers and clinicians with significant advancements in hypertension research since its inception in 1954, with a continued focus on innovative studies through 2024. Ranked Q2 in Internal Medicine and positioned within the top 22% of its category according to Scopus, it is a vital resource for those involved in clinical practice and research aimed at understanding and managing hypertension. The journal disseminates pivotal findings, treatment updates, and guideline recommendations that contribute to improved patient care globally. Accessible solely through subscription, the American Journal of Hypertension is essential reading for professionals committed to enhancing cardiovascular health outcomes.

Therapeutic Innovation & Regulatory Science, published by Springer Heidelberg, is an esteemed journal that focuses on the intersection of therapeutic innovations and the regulatory frameworks that govern them. Established in 1970 and continuing its legacy of excellence through converged years, this journal plays a crucial role in supplying cutting-edge research, reviews, and discussions that advance understanding in the fields of pharmacology and healthcare regulation. With an impact factor reflective of its rigorous peer-review standards, this journal holds a prestigious Q1 ranking in Pharmacology, Toxicology, and Pharmaceutics (Miscellaneous) for 2023, reflecting its influence and the high quality of its published material. The journal's wide scope also embraces public health and environmental studies, making it an essential resource for researchers and professionals navigating these critical areas. Open access options enhance its visibility and accessibility, ensuring that the latest discoveries and regulatory insights are readily available to a global audience. For those at the forefront of medicinal science and regulatory affairs, Therapeutic Innovation & Regulatory Science is your avenue to understanding pivotal innovations that shape contemporary therapeutic practices.

HEALTH TECHNOLOGY ASSESSMENT is a prestigious open-access journal published by the NIHR Journals Library, focusing on advancing the science of health technology assessment through robust research and critical analysis in the fields of Health Policy and Medicine. Since its inception in 2001, this journal has fostered a multidisciplinary approach to evaluating health technologies, offering invaluable insights to researchers, healthcare professionals, and policymakers. With an impressive Q1 ranking in both Health Policy and Medicine (miscellaneous) for 2023, it stands at the forefront of academic discourse, reflecting a high-impact factor and an esteemed reputation within its respective categories. The journal not only publishes original research articles, but also reviews and case studies that illuminate the complexities of health technology in real-world applications. Established and based in the United Kingdom, HEALTH TECHNOLOGY ASSESSMENT strives to encourage evidence-based decision-making, making it an essential resource for anyone committed to enhancing healthcare outcomes through innovative technology assessments.

JTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.

Diabetes Therapy is a prominent open access journal published by SPRINGER HEIDELBERG, dedicated to advancing our understanding of diabetes management and therapeutic strategies. Since its inception in 2010, the journal has provided a platform for high-quality research, showcasing innovative studies and clinical advances aimed at improving care for individuals with diabetes. With an established impact factor and categorized within the Q2 quartile in both Endocrinology, Diabetes and Metabolism and Internal Medicine in 2023, it ranks among the top journals in its field, reflecting its significant contribution to medical knowledge. Researchers, healthcare professionals, and students benefit from its comprehensive coverage of critical topics, ranging from pharmacological advancements to lifestyle interventions and cutting-edge technologies in diabetes management. With a Scopus rank placing it 35th in Internal Medicine, and 68th in Endocrinology, Diabetes, and Metabolism, Diabetes Therapy is recognized for its robust peer-reviewed content, making it an essential resource for anyone engaged in diabetes research and care.

Reviews on Recent Clinical Trials, published by Bentham Science Publishers Ltd, is a distinguished journal in the medical and pharmacological fields, assessing the latest advancements in clinical research since its inception in 2006. With a focus on integrating multidisciplinary approaches to evaluating clinical trial methodologies, the journal caters to a diverse audience of researchers, professionals, and students keen on enhancing their knowledge and understanding of innovative therapeutic strategies and drug developments. Notably positioned in the Q3 quartile as ranked by Scopus for both 'Medicine (miscellaneous)' and 'Pharmacology', the journal illustrates a growing academic influence, evidenced by its Scopus rankings—holding a commendable 72nd percentile in general medicine and a 33rd percentile in pharmacology. While the journal is not open access, it remains committed to disseminating high-quality, peer-reviewed content that drives forward the conversation in clinical research. For those interested in staying abreast of novel findings and comprehensive reviews within the clinical trial landscape, Reviews on Recent Clinical Trials stands out as an essential resource.

CURRENT GENE THERAPY is a leading journal in the field of gene therapy, offering a platform for researchers and professionals to publish their findings related to innovative approaches in gene-based treatments. Published by Bentham Science Publishers Ltd, this journal, with its ISSN 1566-5232 and E-ISSN 1875-5631, is indexed in respected databases, enhancing its visibility and impact in the scientific community. As of 2023, it holds a commendable impact factor, with categorized quartile rankings reflecting its influence, especially in Drug Discovery (Q2), Genetics (Q3), and Molecular Medicine (Q3). Although it follows a subscription model, the journal aims to bridge the gap between laboratory research and clinical applications, attracting submissions that provide critical insights into gene therapy advancements from 2001 to 2024. The editorial scope covers various aspects of gene therapy, including experimental studies and clinical trials, underlining its commitment to fostering knowledge that addresses genetic disorders and enhances therapeutic efficacy. Whether you are a researcher, clinician, or student, CURRENT GENE THERAPY serves as an invaluable resource at the forefront of genetic research and medical innovation.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, published by SAGE Publications Ltd, serves as a vital platform in the fields of biochemistry and medicine, showcasing significant research contributions since its inception in 1972. With an Open Access policy implemented in 2012, this journal promotes unrestricted dissemination of knowledge, catering to a global audience and ensuring that critical findings are accessible to researchers, healthcare professionals, and students alike. With an impressive scope spanning diverse biomedical disciplines, the journal ranks in the Q3 quartile for both biochemistry and medicine, affirming its relevance and impact within these evolving fields. Hailing from the United Kingdom, the journal is dedicated to fostering a rich academic dialogue that bridges laboratory discoveries and clinical applications, making it an essential resource for those engaged in international medical research. Its ongoing commitment to excellence is reflected in its convergence until 2024, inviting high-quality submissions that contribute to advancements in medical science.

PHARMACEUTICAL STATISTICS is a premier academic journal published by Wiley, focusing on the intersection of pharmacology and statistics. With the ISSN 1539-1604 and E-ISSN 1539-1612, this journal has established itself as a leading resource in the field since its inception in 2004, with a targeted convergence year extending to 2024. Notably, it ranks in the Q1 category for both pharmacology and statistics, reflecting its high impact and significance within these disciplines. The journal embraces a wide scope, encompassing statistical methodology and its application in pharmaceuticals, thus serving as an essential platform for researchers, professionals, and students committed to advancing their knowledge and practice. Its notable placement in Scopus rankings further reinforces its academic credibility, making it a valuable reference point for high-quality research. Although this journal does not currently offer open access options, it remains a vital source of insights and research advancements in the pharmaceutical sciences.